200 related articles for article (PubMed ID: 34407735)
1. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Pirosa MC; Zhang L; Hitz F; Novak U; Hess D; Terrot T; Pascale M; Mazzucchelli L; Bertoni F; Cavalli F; Zucca E; Stathis A
Leuk Lymphoma; 2022 Jan; 63(1):117-123. PubMed ID: 34407735
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Ogura M; Tobinai K; Hatake K; Davies A; Crump M; Ananthakrishnan R; Ishibashi T; Paccagnella ML; Boni J; Vandendries E; MacDonald D
Clin Cancer Res; 2016 Oct; 22(19):4807-4816. PubMed ID: 27154915
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Ogura M; Hatake K; Ando K; Tobinai K; Tokushige K; Ono C; Ishibashi T; Vandendries E
Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.
Ogura M; Tobinai K; Hatake K; Uchida T; Kasai M; Oyama T; Suzuki T; Kobayashi Y; Watanabe T; Azuma T; Mori M; Terui Y; Yokoyama M; Mishima Y; Takahashi S; Ono C; Ohata J
Cancer Sci; 2010 Aug; 101(8):1840-5. PubMed ID: 20491780
[TBL] [Abstract][Full Text] [Related]
5. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
[TBL] [Abstract][Full Text] [Related]
6. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
7. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
9. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
10. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
[TBL] [Abstract][Full Text] [Related]
11. Inotuzumab Ozogamicin: First Pediatric Approval.
Dhillon S
Paediatr Drugs; 2024 Jul; 26(4):459-467. PubMed ID: 38780741
[TBL] [Abstract][Full Text] [Related]
12. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
13. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Sangha R; Davies A; Dang NH; Ogura M; MacDonald DA; Ananthakrishnan R; Paccagnella ML; Vandendries E; Boni J; Goh YT
J Drug Assess; 2017; 6(1):10-17. PubMed ID: 28959500
[No Abstract] [Full Text] [Related]
15. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.
Rytting M; Triche L; Thomas D; O'Brien S; Kantarjian H
Pediatr Blood Cancer; 2014 Feb; 61(2):369-72. PubMed ID: 24000241
[TBL] [Abstract][Full Text] [Related]
17. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
Kantarjian H; Thomas D; Jorgensen J; Jabbour E; Kebriaei P; Rytting M; York S; Ravandi F; Kwari M; Faderl S; Rios MB; Cortes J; Fayad L; Tarnai R; Wang SA; Champlin R; Advani A; O'Brien S
Lancet Oncol; 2012 Apr; 13(4):403-11. PubMed ID: 22357140
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Goy A; Forero A; Wagner-Johnston N; Christopher Ehmann W; Tsai M; Hatake K; Ananthakrishnan R; Volkert A; Vandendries E; Ogura M
Br J Haematol; 2016 Aug; 174(4):571-81. PubMed ID: 27101934
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
20. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
